This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stewart, W. J. Articles by Ryan, T. J. Search for Related Content PubMed PubMed Citation Articles by Stewart, W. J. Articles by Ryan, T. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Type 1 Hazardous Substances DB EPINEPHRINE PROTAMINE

Circulation, Vol 70, 788-792, Copyright © 1984 by American Heart Association

ARTICLES

Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization

WJ Stewart, SM McSweeney, MA Kellett, DP Faxon and TJ Ryan

Protamine is widely used for reversing systemic heparinization after cardiac catheterization. Although rare, major reactions to protamine that simulate anaphylaxis occasionally occur and have previously been associated only with an allergic reaction to fish. Because neutral protamine Hagedorn (NPH) insulin includes protamine, it might be anticipated that NPH insulin-dependent diabetic patients would develop sensitivity to protamine. Of 866 consecutive patients undergoing cardiac catheterization over a 20 month period, 651 received protamine for reversal of heparinization. Of these, 8.5% (56/651) were diabetics and 2.3% (15/651) were NPH insulin-dependent diabetics. During this period seven patients were observed immediately after administration of protamine to have major adverse reactions that required the administration of catecholamines. One death ensued. Of the seven major reactions, four occurred in NPH insulin-dependent diabetics and one occurred in a patient with an allergy to fish. The incidence of major protamine reactions was 27% (4/15) in the NPH insulin-dependent diabetics vs 0.5% (3/636) in those with no history of NPH insulin use (p less than .001). This represents a 50-fold increased risk of a major reaction to protamine if the patient was receiving NPH insulin. Accordingly, we recommend that diabetics on NPH insulin and patients with allergies to fish undergo cardiac catheterization without the use of protamine or, when necessary, that protamine be administered cautiously in anticipation of a major adverse reaction.

This article has been cited by other articles:

				J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama, and J. I. Weitz Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 141S - 159S. [Abstract] [Full Text] [PDF]

				J. H. Levy and N. F. Adkinson Jr Anaphylaxis During Cardiac Surgery: Implications for Clinicians Anesth. Analg., February 1, 2008; 106(2): 392 - 403. [Abstract] [Full Text] [PDF]

				S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner Immunological Responses to Exogenous Insulin Endocr. Rev., October 1, 2007; 28(6): 625 - 652. [Abstract] [Full Text] [PDF]

				J. Hirsh and R. Raschke Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 188S - 203S. [Abstract] [Full Text] [PDF]

				F. Viaro, M. B. Dalio, and P. R. B. Evora MD Catastrophic Cardiovascular Adverse Reactions to Protamine Are Nitric Oxide/Cyclic Guanosine Monophosphate Dependent and Endothelium Mediated* : Should Methylene Blue Be the Treatment of Choice? Chest, September 1, 2002; 122(3): 1061 - 1066. [Abstract] [Full Text] [PDF]

				T. M. Bashore, E. R. Bates, P. B. Berger, D. A. Clark, J. T. Cusma, G. J. Dehmer, M. J. Kern, W. K. Laskey, M. P. O'Laughlin, S. Oesterle, et al. American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on Cardiac Catheterization Laboratory Standards: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents endorsed by the American Heart Association and the Diagnostic and Interventional Catheterization Committee of the Council on Clinical Cardiology of the AHA J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2170 - 2214. [Full Text] [PDF]

				J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119(1_suppl): 64S - 94S. [Full Text] [PDF]

				D. Pevni, J. Gurevich, I. Frolkis, G. Keren, I. Shapira, J. Paz, A. Kramer, C. Locker, and R. Mohr Protamine induces vasorelaxation of human internal thoracic artery by endothelial NO-synthase pathway Ann. Thorac. Surg., December 1, 2000; 70(6): 2050 - 2053. [Abstract] [Full Text] [PDF]

				S. E. Kimmel, M. A. Sekeres, J. A. Berlin, N. Ellison, V. J. DiSesa, and B. L. Strom Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1916 - 1922. [Abstract] [Full Text] [PDF]

				G. J. Dehmer, M. Fisher, D. A. Tate, S. Teo, and E. M. Bonnem Reversal of Heparin Anticoagulation by Recombinant Platelet Factor 4 in Humans Circulation, April 15, 1995; 91(8): 2188 - 2194. [Abstract] [Full Text]